Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01419041 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function

A Phase 1 study, sponsored by Pfizer.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target

NCT01419041 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 16 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01419041, a Phase 1 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target

Study Summary

The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.

Interventions

  • DRUG crizotinib

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2011-11
Est. Completion 2012-08
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01419041

The ClinicalTrials.gov registry entry for NCT01419041 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which crizotinib is the first listed.

NCT01419041 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01419041 about?

NCT01419041 is a clinical study titled "A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function". The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.

What is the current status of trial NCT01419041?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-11. Estimated completion is 2012-08.

What interventions are being tested in trial NCT01419041?

The interventions under investigation include: crizotinib (DRUG).

Who is sponsoring clinical trial NCT01419041?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.